Navigation Links
Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
Date:12/1/2008

PT. RICHMOND, Calif., Dec. 1 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to participate at the RBC Capital Markets 2008 Healthcare Conference in New York City on a panel entitled "Delivering Novel Drug Solutions: The Future of Drug Delivery." This presentation is scheduled to take place on Thursday, December 11, 2008 at 1:30 PM Eastern Time.

An audio webcast of the presentation will be available at http://www.transcept.com. The replay of the presentation will be available for 30 days.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and, on September 30, 2008, Transcept submitted a New Drug Application to the U.S. Food and Drug Administration.

For further information, please visit the company's website at: http://www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such stateme
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
2. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
3. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
4. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
5. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
6. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
9. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
10. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...in younger women may up chances of disease, study ...s) -- Mammograms may actually boost the risk of br...uggests. , Dutch researchers analyzed six previ... of low-dose radiation exposure from mammography a...st cancer risk and two looking at the effect of ra...
(Date:12/1/2009)... Pilots will enable local organizations to te...r for consumers who lack access , ...en Fund, a nonprofit venture firm addressing pover...t has selected four organizations in Kenya to cond... transportation and storage. , , ,The pilot progra...
(Date:12/1/2009)..., IRVINE, Calif., Dec. 1 ...CO-Oximetry(TM) and Measure-Through Motion and Low...arance of its latest innovation -- Masimo Rainbow ...sive and continuous respiration rate (RRa(TM)) tha...ompliance. Masimo Rainbow SET Acoustic Monitoring...
(Date:12/1/2009)... Free hearing aids will be given by Estes Aud... Austin, TX (PRWEB) December...m ), a professional hearing healthcare provider de...ired and their families, announced today the begin...giveaway. Each year, Estes Audiology donates two ...
(Date:12/1/2009)... All Federal and Georgia State Retirees who a.... This new benefit is part of the Medicare Advanta...fee for service (PFFS) Options offered by CIGNA, B...r Permanente. Atlanta Hearing Associates has three... Oconee / Greensboro, GA and Lake Sinclair / Mille...
Breaking Medicine News(10 mins):Health News:Mammograms May Boost Cancer Risk in High-Risk Women 2Health News:Acumen Fund Announces Ripple Effect Pilot Projects In Kenya To Identify Innovative Solutions To Water Challenges 2Health News:Acumen Fund Announces Ripple Effect Pilot Projects In Kenya To Identify Innovative Solutions To Water Challenges 3Health News:Acumen Fund Announces Ripple Effect Pilot Projects In Kenya To Identify Innovative Solutions To Water Challenges 4Health News:Masimo Receives FDA Clearance for Masimo Rainbow SET(R) Acoustic Respiration Rate Monitoring 2Health News:Masimo Receives FDA Clearance for Masimo Rainbow SET(R) Acoustic Respiration Rate Monitoring 3Health News:Masimo Receives FDA Clearance for Masimo Rainbow SET(R) Acoustic Respiration Rate Monitoring 4Health News:Masimo Receives FDA Clearance for Masimo Rainbow SET(R) Acoustic Respiration Rate Monitoring 5Health News:Masimo Receives FDA Clearance for Masimo Rainbow SET(R) Acoustic Respiration Rate Monitoring 6Health News:Estes Audiology Offers the Gift of Hearing to Celebrate the Holiday Season 2Health News:Retired Fed. & GA State Employees Get New Hearing Healthcare Benefit, Jan. 2010 2Health News:Retired Fed. & GA State Employees Get New Hearing Healthcare Benefit, Jan. 2010 3Health News:Retired Fed. & GA State Employees Get New Hearing Healthcare Benefit, Jan. 2010 4
...to offer good news for older adults .The first stu... depression // in the elderly. Researchers studied...participants suffered from major depression, while...study show seniors who received the home-based pro...
...ng pneumonia may mean just a short-term lease on a...lts of the study show // increasing age combined w...e, an altered mental state, and anemia were signif...olled diabetes and a hematocrit (ratio of the volu...
...tion after heart surgery may not be the be the wis...archers.// A recent study confirms that corona...heart medications, such as beta blockers and ACE i...edication. However, this assumption was questioned...
...e conditions such as chronic bronchitis and emphys... // and gradual loss of lung function that cannot ...use of death in the United States. A test known...pirometry test and a screening questionnaire to de...
...tendon near a joint becomes inflamed. Treatment is... a new approach relieves the pain of this common c... with tendonitis are finding relief with extracorp...ave treatments to relieve the pain of chronic tend...
...dy researchers say zinc supplements may increase t...ttention deficit hyperactivity // disorder ( ADHD ...n of melatonin, which helps regulate dopamine func... of reward and pleasure. Zinc is a mineral tha...
Other Medicine News:
(Date:11/30/2009)...C., Nov. 30 Microban International...l product protection, is pleased to announce their... Corp., the largest U.S. manufacturer and distribu...orp is launching two new lines of ceramic tile wit...;) patent pending silver based technology, in orde...
(Date:11/30/2009)...PRNewswire/ -- Breast-Specific Gamma Imaging (BSGI... technique for the detection of ductal carcinoma i...er. BSGI is a molecular breast imaging technique t...and discover very early stage cancers. According t...f the Radiological Society of North America (RSNA)...
(Date:11/30/2009)..., Nov. 30 SCOLR Pharma, ...vember 25, 2009, the NYSE Amex LLC (the "Exchange"...mpany,s plan to comply with its previously disclos... the Exchange Company Guide. Specifically, the de...losses which were so substantial in relation to it...
Breaking Medicine Technology:Dal-Tile Corp. Launches Two New Lines of Ceramic Tile with Microban(R) Silver Antimicrobial Technology 2Breast-Specific Gamma Imaging Proves Highly Sensitive for the Detection of Ductal Carcinoma In Situ 2SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4University of Louisville neuroscientists hope to get people walking again 58667 1Experts gather at McGill University to address food security challenges 10216 1EPA reviews Univ of Michigan dioxin study 10212 1EPA reviews Univ of Michigan dioxin study 10212 2
... EnVivo Pharmaceuticals, Inc.,a privately held bio...egenerative diseases, today announced progress on ...chizophrenia and Huntington,s,diseases. EnVivo Ph...orally,active Alpha 7 Nicotinic Acetylcholine Rece...ts associated with Alzheimer,s disease and,Schizop...
...h Joint Venture Between Bristol-Myers Squibb, Co...n HIV Treatment -, PRINCETON, N.J. and FOSTER CIT...ol-Myers Squibb Company (NYSE: BMY ) and Gilead S...t Health Canada has approved ATRIPLA(R),(efavirenz...fumarate 300,mg) for the treatment of HIV-1 infect...
Other Medicine Technology:EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9
.../See™ is a 1-step, hand-held, point-of-care ...ug metabolites in human urine. The TOX/See device... drugs in 3 to 8 minutes and requires only a few d...ly packaged to maximize convenience and ease of us...
ESR-10 Manual Rack
...eck Cytometry Concentrate is for use as a sheath f...ach 70ml bottle of Cytometry Concentrate dilutes t...d to Cubitainers, Streck Cytometry Concentrate red...es money without compromising performance. Streck ...
CD-Chex CD34 Leukocyte Control
Medicine Products: